EASL recommendations on treatment of hepatitis C: Final update of the series☆
Jean–Michel Pawlotsky, Francesco Negro, Alessio Aghemo et al. · Journal of Hepatology · 2020
Cited by 1,252 works. doi:10.1016/j.jhep.2020.08.018
Authors
- Jean–Michel Pawlotsky
- Francesco Negro
- Alessio Aghemo
- Marina Berenguer
- Olav Dalgård
- Geoffrey M Dusheiko
- Fiona Marra
- Massimo Puoti
- Heiner H. Wedemeyer
References
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
- Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
- EASL Recommendations on Treatment of Hepatitis C 2018
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
- GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations
- Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
- EASL Recommendations on Treatment of Hepatitis C 2015
- EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis